Phase II Study on SCH 66336 (Farnesyl Protein Transferase Inhibitor) [lonafarnib] and Gemcitabine as Second Line Treatment in Advanced Metastatic Urothelial Cancer - EORTC Study 16997
Phase of Trial: Phase II
Latest Information Update: 21 Sep 2012
At a glance
- Drugs Lonafarnib (Primary) ; Gemcitabine
- Indications Urogenital cancer
- Focus Therapeutic Use
- 12 Sep 2005 New trial record.